Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (CNTX) is a clinical-stage biopharmaceutical company focused on T cell engaging (TCE) bispecific antibodies for solid tumors. The CNTX news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how its pipeline and corporate activities evolve over time.
According to recent announcements, Context is advancing three key programs: CTIM-76, a Claudin 6 x CD3 TCE in a Phase 1 dose-escalation trial for CLDN6-positive ovarian, endometrial, and testicular cancers; CT-95, a Mesothelin x CD3 TCE in a Phase 1 study for mesothelin-expressing solid tumors such as pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancers; and CT-202, a Nectin-4 x CD3 TCE in preclinical development with pH-dependent activity designed for the tumor microenvironment. News items often highlight clinical enrollment updates, early safety and anti-tumor activity signals, and preclinical data presented at major oncology meetings.
Investors and followers of CNTX can also see updates on quarterly operating and financial results, at-the-market equity program changes, Nasdaq listing compliance notices and resolutions, and organizational developments such as inducement stock option grants and senior leadership appointments. The company regularly reports participation in scientific and investor conferences, including ASCO, AACR, SITC, and healthcare investment forums, which can signal upcoming data disclosures or corporate visibility efforts.
Use this page to review Context Therapeutics’ latest clinical, financial, and corporate news in one place. For those tracking immuno-oncology and T cell engager developments in solid tumors, the CNTX news stream provides a consolidated view of the company’s reported progress and key milestones.
Context Therapeutics (NASDAQ:CNTX) will present two poster presentations at the Society for Immunotherapy of Cancer 40th Annual Meeting, November 7–9, 2025, in National Harbor, MD.
One poster is a Trial in Progress for the Phase 1, first‑in‑human study of CT-95 (mesothelin x CD3 TCE) in advanced solid tumors (Abstract #586), scheduled Saturday, November 8, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls. The second poster covers preclinical efficacy, safety, and PK data for CT-202 (Nectin-4 x CD3 TCE) (Abstract #963), scheduled Friday, November 7, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls.
Abstracts are available via the SITC 40th Annual Meeting website.
Context Therapeutics (Nasdaq: CNTX) granted a non-qualified stock option inducement to a new employee on October 1, 2025 under Nasdaq Listing Rule 5635(c)(4). The award covers 30,000 shares with an exercise price of $0.97 per share (Nasdaq closing price on the grant date). Options have a 10‑year term and vest over 4 years: 25% on the first anniversary and the remaining 75% in 36 equal monthly installments, subject to continued service. The grant was made outside the company’s 2021 Long‑Term Performance Incentive Plan as permitted by Nasdaq rule as an inducement for employment.
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumors, has announced its participation in two upcoming investor conferences.
The company will present at the Cantor Global Healthcare Conference 2025 on September 3 with a fireside chat at 10:55 AM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 with a fireside chat at 3:30 PM ET. Both events will be held in New York, NY and include one-on-one meeting opportunities with management.
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, reported Q2 2025 financial results and pipeline updates. The company maintains a strong financial position with $83.5 million in cash, expected to fund operations into 2027. Context is advancing two key clinical programs: CTIM-76 (CLDN6 x CD3 bispecific antibody) and CT-95 (MSLN x CD3 bispecific antibody), with initial data expected in 2026.
The company reported a net loss of $8.8 million for Q2 2025, with R&D expenses increasing to $7.8 million compared to $1.4 million in Q2 2024. Notable developments include the first patient dosed in the CT-95 Phase 1 trial and the appointment of Dr. Karen Chagin as Chief Medical Officer.
Context Therapeutics (NASDAQ: CNTX) has appointed Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin brings significant expertise in T cell therapy development, having previously served as Senior Vice President at Adaptimmune where she contributed to the approval of Tecelra®, the first engineered cell therapy approved for solid tumors in the U.S. She also held the CMO position at Tmunity before its acquisition by Kite Pharma.
Dr. Chagin succeeds interim CMO Dr. Karen Smith, who will remain on the Company's Board. As part of her employment agreement, Dr. Chagin will receive an inducement grant of 153,000 stock options, vesting over four years, with an exercise price set at the closing price on her employment start date.
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, has granted inducement stock options to two new employees. The grants total 160,000 shares of common stock, awarded outside the company's 2021 Long-Term Performance Incentive Plan. The options were granted on May 5 and May 12, 2025, with exercise prices of $0.839 and $0.78 per share respectively. These 10-year options vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the following three years, contingent on continued employment.
Context Therapeutics (NASDAQ: CNTX) announced a leadership transition as Dr. Karen Smith takes over as interim Chief Medical Officer (CMO), replacing Dr. Claudio Dansky Ullmann who will depart on May 10, 2025. Dr. Smith, currently a Board member, will serve in a dual capacity while the company searches for a permanent CMO.
Dr. Smith brings over 20 years of experience in drug development and commercialization, having previously served as Global Head of R&D and CMO at Jazz Pharmaceuticals, with additional senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb. She will oversee the company's clinical development programs during this transition period.
Context Therapeutics presented preclinical and translational data for their cancer treatment candidate CT-95 at the 2025 AACR Annual Meeting in Chicago. CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody designed to treat solid tumors.
Key findings from the preclinical studies show that CT-95:
- Selectively binds to mesothelin-expressing cells
- Targets a unique membrane-proximal region of mesothelin
- Avoids impact of shed mesothelin sink
- Demonstrates high activity and good tolerance in various models
- Activates T cells without broad cytokine release
The company has already begun Phase 1 clinical trials and expects to share initial clinical data by mid-2026. The treatment targets mesothelin expressing cancers, including pancreatic, ovarian, and mesothelioma, addressing a significant unmet medical need.